Impact of Subthalamic Deep Brain Stimulation on Impulse Control Disorders in Parkinson's Disease: A Prospective Study.


Journal

Movement disorders : official journal of the Movement Disorder Society
ISSN: 1531-8257
Titre abrégé: Mov Disord
Pays: United States
ID NLM: 8610688

Informations de publication

Date de publication:
03 2021
Historique:
revised: 02 09 2020
received: 19 05 2020
accepted: 10 09 2020
pubmed: 7 10 2020
medline: 28 4 2021
entrez: 6 10 2020
Statut: ppublish

Résumé

Impact of subthalamic deep brain stimulation (DBS) on impulse control disorders (ICD) in Parkinson's disease (PD) remains controversial. The objectives of this study were to analyze the natural history of ICD between baseline and 1 year after subthalamic DBS in patients with PD and to identify predictive factors, taking into account the positions of the active contact and stimulation parameters. We analyzed postoperative modifications of ICD based on the multicentric, prospective Predictive Factors and Subthalamic Stimulation in Parkinson's Disease cohort. ICD status and Ardouin Scale of Behaviour in PD were assessed at baseline and 1 year following subthalamic DBS. Location of active contacts within the 3 subthalamic nucleus functional territories was investigated. A total of 217 were patients included. Of the patients, 10.6% had ICD at baseline of which 95.6% improved at 1 year following subthalamic DBS; 3.6% of the patients experienced de novo ICD at 1 year following subthalamic DBS. Dopamine agonist dose reduction (from 309.8 to 109.3 mg) was the main driver of ICD regression (P = 0.05). Higher preoperative dyskinesias were associated with poorer ICD evolution (P = 0.04). Whereas baseline apathy was a risk factor of de novo ICD (P = 0.02), ICD improvement correlated with postoperative apathy (P = 0.004). Stimulation power and position of active contacts-mainly located within the sensorimotor part of the subthalamic nucleus-did not influence ICD. This 1-year, postoperative follow-up study showed ICD regression and dopaminergic drug reduction with optimal position of the active contacts within the subthalamic nucleus. Whereas patients with PD with preoperative ICD were prone to postoperative apathy, we also showed that those with preoperative apathy had a higher risk to experience postoperative de novo ICD, further highlighting the meaningful influence of postoperative management of dopaminergic medication on outcome and the continuum between apathy and ICD. © 2020 International Parkinson and Movement Disorder Society.

Sections du résumé

BACKGROUND
Impact of subthalamic deep brain stimulation (DBS) on impulse control disorders (ICD) in Parkinson's disease (PD) remains controversial.
OBJECTIVES
The objectives of this study were to analyze the natural history of ICD between baseline and 1 year after subthalamic DBS in patients with PD and to identify predictive factors, taking into account the positions of the active contact and stimulation parameters.
METHODS
We analyzed postoperative modifications of ICD based on the multicentric, prospective Predictive Factors and Subthalamic Stimulation in Parkinson's Disease cohort. ICD status and Ardouin Scale of Behaviour in PD were assessed at baseline and 1 year following subthalamic DBS. Location of active contacts within the 3 subthalamic nucleus functional territories was investigated.
RESULTS
A total of 217 were patients included. Of the patients, 10.6% had ICD at baseline of which 95.6% improved at 1 year following subthalamic DBS; 3.6% of the patients experienced de novo ICD at 1 year following subthalamic DBS. Dopamine agonist dose reduction (from 309.8 to 109.3 mg) was the main driver of ICD regression (P = 0.05). Higher preoperative dyskinesias were associated with poorer ICD evolution (P = 0.04). Whereas baseline apathy was a risk factor of de novo ICD (P = 0.02), ICD improvement correlated with postoperative apathy (P = 0.004). Stimulation power and position of active contacts-mainly located within the sensorimotor part of the subthalamic nucleus-did not influence ICD.
CONCLUSIONS
This 1-year, postoperative follow-up study showed ICD regression and dopaminergic drug reduction with optimal position of the active contacts within the subthalamic nucleus. Whereas patients with PD with preoperative ICD were prone to postoperative apathy, we also showed that those with preoperative apathy had a higher risk to experience postoperative de novo ICD, further highlighting the meaningful influence of postoperative management of dopaminergic medication on outcome and the continuum between apathy and ICD. © 2020 International Parkinson and Movement Disorder Society.

Identifiants

pubmed: 33022101
doi: 10.1002/mds.28320
doi:

Banques de données

ClinicalTrials.gov
['NCT02360683']

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

750-757

Informations de copyright

© 2020 International Parkinson and Movement Disorder Society.

Références

Vilas D, Pont-Sunyer C, Tolosa E. Impulse control disorders in Parkinson's disease. Parkinsonism Relat Disord 2012;18:S80-S84.
Lhommée E, Klinger H, Thobois S, et al. Subthalamic stimulation in Parkinson's disease: restoring the balance of motivated behaviours. Brain 2012;135(5):1463-1477.
Lhommée E, Wojtecki L, Czernecki V, et al. Behavioural outcomes of subthalamic stimulation and medical therapy versus medical therapy alone for Parkinson's disease with early motor complications (EARLYSTIM trial): secondary analysis of an open-label randomised trial. Lancet Neurol 2018;17(3):223-231.
Amami P, Dekker I, Piacentini S, et al. Impulse control behaviours in patients with Parkinson's disease after subthalamic deep brain stimulation: de novo cases and 3-year follow-up. J Neurol Neurosurg Psychiat 2015;86(5):562-564.
Kasemsuk C, Oyama G, Hattori N. Management of impulse control disorders with deep brain stimulation: a double-edged sword. J Neurol Sci 2017;374:63-68.
Mallet L, Schupbach M, N'Diaye K, et al. Stimulation of subterritories of the subthalamic nucleus reveals its role in the integration of the emotional and motor aspects of behavior. Proc Natl Acad Sci U S A 2007;104(25):10661-10666.
Broen M, Duits A, Visser-Vandewalle V, Temel Y, Winogrodzka A. Impulse control and related disorders in Parkinson's disease patients treated with bilateral subthalamic nucleus stimulation: a review. Parkinsonism Relat Disord 2011;17(6):413-417.
Evans AH, Okai D, Weintraub D, et al. Scales to assess impulsive and compulsive behaviors in Parkinson's disease: critique and recommendations. Mov Disord 2019;34(6):791-798.
Cormier-Dequaire F, Bekadar S, Anheim M, et al. Suggestive association between OPRM1 and impulse control disorders in Parkinson's disease: OPRM1 and ICDS in Parkinson's disease. Mov Disord 2018;33(12):1878-1886.
Koss AM, Alterman RL, Tagliati M, Shils JL. Calculating total electrical energy delivered by deep brain stimulation systems. Ann Neurol 2005;58(1):168-168.
Yelnik J, Bardinet E, Dormont D, et al. A three-dimensional, histological and deformable atlas of the human basal ganglia. I. Atlas construction based on immunohistochemical and MRI data. NeuroImage 2007;34(2):618-638.
Bardinet E, Bhattacharjee M, Dormont D, et al. A three-dimensional histological atlas of the human basal ganglia. II. Atlas deformation strategy and evaluation in deep brain stimulation for Parkinson disease. J Neurosurg 2009;110(2):208-219.
Kim YE, Kim HJ, Kim H-J, et al. Impulse control and related behaviors after bilateral subthalamic stimulation in patients with Parkinson's disease. J Clin Neurosci 2013;20(7):964-969.
Kim A, Kim YE, Kim H-J, et al. A 7-year observation of the effect of subthalamic deep brain stimulation on impulse control disorder in patients with Parkinson's disease. Parkinsonism Relat Disord 2018;56:3-8.
Kurtis MM, Rajah T, Delgado LF, Dafsari HS. The effect of deep brain stimulation on the non-motor symptoms of Parkinson's disease: a critical review of the current evidence. NPJ Parkinson's Dis 2017;3(1):16024.
Gatto EM, Aldinio V. Impulse control disorders in Parkinson's disease. A brief and comprehensive review. Front Neurol 2019;10:351.
Demetriades P, Rickards H, Cavanna AE. Impulse control disorders following deep brain stimulation of the subthalamic nucleus in Parkinson's disease: clinical aspects. Parkinson's Dis 2011;2011:1-9.
Thobois S, Ardouin C, Lhommee E, et al. Non-motor dopamine withdrawal syndrome after surgery for Parkinson's disease: predictors and underlying mesolimbic denervation. Brain 2010;133(4):1111-1127.
Rodriguez-Oroz MC, López-Azcárate J, Garcia-Garcia D, et al. Involvement of the subthalamic nucleus in impulse control disorders associated with Parkinson's disease. Brain 2011;134(1):36-49.
Hinkle JT, Perepezko K, Rosenthal LS, et al. Markers of impaired motor and cognitive volition in Parkinson's disease: correlates of dopamine dysregulation syndrome, impulse control disorder, and dyskinesias. Parkinsonism Relat Disord 2018;47:50-56.
Biundo R, Weis L, Abbruzzese G, et al. Impulse control disorders in advanced Parkinson's disease with dyskinesia: the ALTHEA study: ICD and related behaviors in PD with dyskinesia. Mov Disord 2017;32(11):1557-1565.
Starr PA, Christine CW, Theodosopoulos PV, et al. Implantation of deep brain stimulators into subthalmic nucleus: technical approach and magnetic imaging-verified electrode locations. J Neurosurg 2002;97(2):370-387.
Herzog J, Fietzek U, Hamel W, et al. Most effective stimulation site in subthalamic deep brain stimulation for Parkinson's disease. Mov Disord 2004;19(9):1050-1054.
Pollo C, Vingerhoets F, Pralong E, et al. Localization of electrodes in the subthalamic nucleus on magnetic resonance imaging. J Neurosurg 2007;106(1):36-44.
Benabid AL, Chabardes S, Mitrofanis J, Pollak P. Deep brain stimulation of the subthalamic nucleus for the treatment of Parkinson's disease. Lancet Neurol 2009;8(1):67-81.
Welter M-L, Schupbach M, Czernecki V, et al. Optimal target localization for subthalamic stimulation in patients with Parkinson disease. Neurology 2014;82(15):1352-1361.
Mosley PE, Smith D, Coyne T, Silburn P, Breakspear M, Perry A. The site of stimulation moderates neuropsychiatric symptoms after subthalamic deep brain stimulation for Parkinson's disease. NeuroImage 2018;18:996-1006.

Auteurs

Marie des Neiges Santin (MDN)

Department of Neurosurgery, NS-PARK/F-CRIN, Strasbourg University Hospital, Strasbourg, France.

Paul Voulleminot (P)

Department of Neurology, NS-PARK/F-CRIN, Strasbourg University Hospital, Fédération de Médecine Translationnelle de Médecine de Strasbourg, Strasbourg, France.

Agathe Vrillon (A)

Department of Neurology, NS-PARK/F-CRIN, Assistance Publique - Hôpitaux de Paris (APHP), Pitié-Salpêtrière Hospital, Paris, France.

Elodie Hainque (E)

Department of Neurology, NS-PARK/F-CRIN, Assistance Publique - Hôpitaux de Paris (APHP), Pitié-Salpêtrière Hospital, Paris, France.
Sorbonne Universités, Assistance Publique - Hôpitaux de Paris (APHP), Inserm, CNRS, Institut du Cerveau et de la Moelle (ICM), Paris, France.

Matthieu Béreau (M)

Department of Neurology, NS-PARK/F-CRIN, University Hospital of Besançon, Besançon, France.

Ouhaid Lagha-Boukbiza (O)

Department of Neurology, NS-PARK/F-CRIN, Strasbourg University Hospital, Fédération de Médecine Translationnelle de Médecine de Strasbourg, Strasbourg, France.

Thomas Wirth (T)

Department of Neurology, NS-PARK/F-CRIN, Strasbourg University Hospital, Fédération de Médecine Translationnelle de Médecine de Strasbourg, Strasbourg, France.

Solveig Montaut (S)

Department of Neurology, NS-PARK/F-CRIN, Strasbourg University Hospital, Fédération de Médecine Translationnelle de Médecine de Strasbourg, Strasbourg, France.

Eric Bardinet (E)

Department of Neurology, NS-PARK/F-CRIN, University Hospital of Besançon, Besançon, France.
Centre de Neuroimagerie de Recherche, Institut du Cerveau et de la Moelle (ICM), Paris, France.

Maeva Kyheng (M)

Department of Clinical Research, Lille University Hospital, Lille, France.

Anne-Sophie Rolland (AS)

Department of Medical Pharmacology, University Hospital, NS-PARK/F-CRIN, University of Lille, Lille Neuroscience & Cognition, Inserm, UMR-S1172, Lille, France.

Jimmy Voirin (J)

Department of Neurosurgery, NS-PARK/F-CRIN, Strasbourg University Hospital, Strasbourg, France.

Sophie Drapier (S)

Department of Neurology, NS-PARK/F-CRIN, University Hospital of Rennes, Rennes, France.

Franck Durif (F)

Department of Neurology, NS-PARK/F-CRIN, CHU Clermont-Ferrand, Clermont-Ferrand, France.

Alexandre Eusebio (A)

Department of Neurology, NS-PARK/F-CRIN, Assistance Publique - Hôpitaux de Marseille (APHM), Timone University Hospital and Institut de Neurosciences de la Timone, Marseille, France.

Caroline Giordana (C)

Department of Neurology, NS-PARK/F-CRIN, Centre Hospitalier Universitaire de Nice, Nice, France.

Nicolas Auzou (N)

Institute of Neurodegenerative Disorders, NS-PARK/F-CRIN, University Hospital of Bordeaux, Bordeaux, France.

Jean-Luc Houeto (JL)

Department of Neurology, NS-PARK/F-CRIN, University Hospital of Poitiers, Poitiers, France.

Cécile Hubsch (C)

Department of Neurology, NS-PARK/F-CRIN, Fondation Ophtalmologique Adolphe de Rothschild, Paris, France.

Béchir Jarraya (B)

Neuroscience Pole, NS-PARK/F-CRIN, Hôpital Foch, Suresnes, University of Versailles Paris-Saclay, INSERM-CEA NeuroSpin, Saclay, France.

Chloé Laurencin (C)

Department of Neurology, NS-PARK/F-CRIN, University Hospital of Lyon, Lyon, France.

David Maltete (D)

Department of Neurology, NS-PARK/F-CRIN, Rouen University Hospital and University of Rouen, France; INSERM U1239, Laboratory of Neuronal and Neuroendocrine Differentiation and Communication, Mont-Saint-Aignan, France.

Mylène Meyer (M)

Department of Neurology, NS-PARK/F-CRIN, University Hospital of Nancy, Nancy, France.

Olivier Rascol (O)

Department of Clinical Pharmacology and Neuroscience, NS-Park/F-CRIN, Toulouse University Hospital, Toulouse, France.

Tiphaine Rouaud (T)

Department of Neurology, NS-PARK/F-CRIN, Nantes University Hospital, Nantes, France.

Mélissa Tir (M)

Department of Neurology, NS-PARK/FCRIN, Amiens University Hospital, Amiens, France.

Caroline Moreau (C)

Department of Neurology, University Hospital, NS-PARK/F-CRIN, University of Lille, Lille Neuroscience & Cognition, INSERM, UMR-S1172, Lille, France.

Jean-Christophe Corvol (JC)

Department of Neurology, NS-PARK/F-CRIN, Assistance Publique - Hôpitaux de Paris (APHP), Pitié-Salpêtrière Hospital, Paris, France.
Sorbonne Universités, Assistance Publique - Hôpitaux de Paris (APHP), Inserm, CNRS, Institut du Cerveau et de la Moelle (ICM), Paris, France.

François Proust (F)

Department of Neurosurgery, NS-PARK/F-CRIN, Strasbourg University Hospital, Strasbourg, France.

David Grabli (D)

Department of Neurology, NS-PARK/F-CRIN, Assistance Publique - Hôpitaux de Paris (APHP), Pitié-Salpêtrière Hospital, Paris, France.

David Devos (D)

Department of Medical Pharmacology, University Hospital, NS-PARK/F-CRIN, University of Lille, Lille Neuroscience & Cognition, Inserm, UMR-S1172, Lille, France.
Department of Neurology, University Hospital, NS-PARK/F-CRIN, University of Lille, Lille Neuroscience & Cognition, INSERM, UMR-S1172, Lille, France.

Christine Tranchant (C)

Department of Neurology, NS-PARK/F-CRIN, Strasbourg University Hospital, Fédération de Médecine Translationnelle de Médecine de Strasbourg, Strasbourg, France.

Mathieu Anheim (M)

Department of Neurology, NS-PARK/F-CRIN, Strasbourg University Hospital, Fédération de Médecine Translationnelle de Médecine de Strasbourg, Strasbourg, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH